DAX24.853 ±-0,0%Est506.011 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,3800 -2,0%Nas22.731 -1,5%Bitcoin55.540 -1,5%Euro1,1864 -0,1%Öl67,69 -2,8%Gold4.948 -2,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Siemens 723610 Mercedes-Benz Group (ex Daimler) 710000 SAP 716460 Deutsche Telekom 555750 Rheinmetall 703000 NVIDIA 918422 BASF BASF11 Gerresheimer A0LD6E Amazon 906866 Lufthansa 823212 Microsoft 870747 Allianz 840400 Bayer BAY001 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich kaum bewegt -- US-Börsen rot -- Mercedes-Benz: Gewinneinbruch -- Siemens erhöht Ergebnisprognose -- TKMS, Deutsche Börse, DroneShield, Birkenstock, Micron, Palantir, Fastly im Fokus
Top News
Gold, Heizöl, Silber & Co. am Donnerstagabend Gold, Heizöl, Silber & Co. am Donnerstagabend
LOréal-Aktie fällt deutlich: Kosmetikkonzern schwächelt im Luxusgeschäft und in China etwas LOréal-Aktie fällt deutlich: Kosmetikkonzern schwächelt im Luxusgeschäft und in China etwas
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
191,40 EUR +5,60 EUR +3,01 %
STU
227,44 USD +6,58 USD +2,98 %
BTT
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.331,15 Mrd. EUR

KGV95,86Div. Rendite2,91%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
ZacksAbbVie (ABBV) Stock Moves -1.73%: What You Should Know
ZacksAbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
PR NewswireAbbVie to Host First-Quarter 2025 Earnings Conference Call
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
PR NewswireAbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
ZacksAbbVie (ABBV) Stock Sinks As Market Gains: Here's Why
PR NewswireAllergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
BenzingaIs AbbVie Gaining or Losing Market Support?
BenzingaAbbVie Options Trading: A Deep Dive into Market Sentiment
MotleyFoolHere's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends
ZacksAbbVie (ABBV) Stock Moves -0.29%: What You Should Know
ZacksThe Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands
PR NewswireELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
ZacksTop Analyst Reports for AbbVie, Lockheed Martin & Dell
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ZacksWhy AbbVie (ABBV) Dipped More Than Broader Market Today
ZacksZacks Market Edge Highlights: Berkshire Hathaway, Aon plc and AbbVie
BenzingaAbbVie Options Trading: A Deep Dive into Market Sentiment
ZacksHere's How to Play AbbVie Stock as it Enters the Obesity Space
Benzinga13 Analysts Have This To Say About AbbVie
PR NewswireAbbVie to Present at the Leerink Partners Global Healthcare Conference
PR NewswireSKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
ZacksAbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
BenzingaAbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
PR NewswireAbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
PR NewswireAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
ZacksAbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
PR NewswireAbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
BenzingaHere's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
ZacksThe Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic
MotleyFoolIs AbbVie Stock a Buy Now?
PR NewswireAbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAllergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
PR NewswireAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
PR NewswireU.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
ZacksThe Zacks Analyst Blog Walmart, Visa, AbbVie and AstroNova
PR NewswireAllergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
PR NewswireAllergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.